QVQ Holding BV
QVQ offers tailor-made VHH-development on inquiry. This includes:
- – Design and implementation of an immunization protocols in llama.
- – Determination of immune responses in the sera.
- – Cloning of VHH-repertoires in phage-display librarie
- – Delivery of different VHHs (sequence and >0.5 mg protein).
QVQ can also deliver larger quantities of VHH for their prospective use in for example (co-)crystallization or in vivo experiments. In addition, QVQ offers directional labeling of VHHs and the oppertunity to produce VHHs in yeast according to GMP conditions, which allows for clinical application.
Two great bi-heads!
QVQ was founded in 2010 by Theo Verrips, Pim Epping, Mohamed El Khattabi, Edward Dolk, and Eefjan Breukink with the aim to develop existing VHH from the Utrecht University and newly obtained proprietary VHH into high quality imaging agents for the early detection of diseases. QVQ has broadened its own portfolio of imaging agents and further developed methodologies for directional functionalization of the VHH for imaging. In collaboration with partners in Dutch medical centres, industrial partners and institutes QVQ is the only company that can develop VHH from the immunization of llamas, library construction, selection, screening and production up to GMP scale for translation to the clinic.